No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LLY240712P940000
- 0.04
- -7.46-99.47%
15min DelayClose Jul 12 15:59 ET
6.41High0.01Low
6.41Open7.50Pre Close2.20K Volume220 Open Interest940.00Strike Price154.05KTurnover43.98%IV0.89%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0246Delta0.0134Gamma23710.00Leverage Ratio-2.9631Theta0.0000Rho-584.11Eff Leverage0.0056Vega
Intraday
- 5D
- Daily
News
Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
GLP-1 Concerns Clobbered This Healthcare Stock. Now It's Time to Buy.
ResMed makes its bank from products that battle sleep apnea. When that business seemed threatened, investors fled. Now it looks like they were too hasty. By Jacob Sonenshine ResMed is the latest
Lilly Expecting Q2 IPR&D Pre-tax Charge of Around $0.14 per Share: Report
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Thursday, Pfizer Inc (NYSE:PFE) announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.Pfizer plans to
Executive Reshuffles: ChargePoint, Tupperware and ADM in Focus
Comments
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
Jim Cramer on Wednesday reviewed eight stocks that could join the “trillion-dollar stock club,” pinpointing pharmaceutical giant Eli Lilly and electric vehicle maker Tesla as top contenders.
Currently, tech giants $Apple(AAPL.US$ , $Microsoft(MSFT.US$ , $NVIDIA(NVDA.US$ , $Alphabet-A(GOOGL.US$ , $Amazon(AMZN.US$ , and $Meta Platforms(META.US$ are the only companies to surpass $1 trillion in market cap.
$Eli Lilly and Co(LLY.US$ : Cramer ...
Currently, tech giants $Apple(AAPL.US$ , $Microsoft(MSFT.US$ , $NVIDIA(NVDA.US$ , $Alphabet-A(GOOGL.US$ , $Amazon(AMZN.US$ , and $Meta Platforms(META.US$ are the only companies to surpass $1 trillion in market cap.
$Eli Lilly and Co(LLY.US$ : Cramer ...
From YouTube
12
3
Read more
I Am 102927471 :